TY - JOUR T1 - Respiratory diseases in survivors of adult cancer compared with the general population: a systematic review protocol JF - BMJ Open JO - BMJ Open DO - 10.1136/bmjopen-2022-066029 VL - 12 IS - 11 SP - e066029 AU - Kirsty Andresen AU - Helena Carreira AU - Jennifer K Quint AU - Krishnan Bhaskaran Y1 - 2022/11/01 UR - http://bmjopen.bmj.com/content/12/11/e066029.abstract N2 - Introduction There is concern that survivors of adult cancers may be at increased risk of respiratory infections and of exacerbations of pre-existing respiratory conditions. Considering the high prevalence of respiratory disease in the general population, increased respiratory disease risk in survivors of adult cancers could translate into an important impact on morbidity and mortality. The aim of this systematic review is to summarise and assess the quality of all studies comparing respiratory outcomes between adult cancer survivors and individuals with no history of cancer.Methods and analysis This systematic literature review will be conducted using Medline, EMBASE and Cochrane. We will include cohort or case–control studies that provide a comparative estimate of the risk of a respiratory disease of interest in survivors of adult cancer against a comparator cohort of cancer-free individuals. No geographic, time or language restrictions will be applied. We will assess the risk of bias using the Scottish Intercollegiate Guidelines Network methodology checklists. Results will be summarised by type of respiratory outcome, cancer type and cancer survivorship definition. If sufficient numbers of homogeneous studies are found, summary measures of association will be calculated using random effects meta-analysis models.Ethics and dissemination Ethical approval is not applicable to our study. The results will be used to identify evidence gaps and priorities for future research to understand respiratory morbidity in survivors of adult cancers and identify possible mitigation strategies. Results from this review will be disseminated to clinical audiences and submitted to a peer-reviewed journal when completed.Trial registration number This study has been registered on PROSPERO (registration number: CRD42022311557). ER -